Robin E. Pearce

3.0k total citations
58 papers, 2.4k citations indexed

About

Robin E. Pearce is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, Robin E. Pearce has authored 58 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pharmacology, 18 papers in Pediatrics, Perinatology and Child Health and 18 papers in Oncology. Recurrent topics in Robin E. Pearce's work include Pharmacogenetics and Drug Metabolism (39 papers), Drug Transport and Resistance Mechanisms (16 papers) and Pharmaceutical studies and practices (10 papers). Robin E. Pearce is often cited by papers focused on Pharmacogenetics and Drug Metabolism (39 papers), Drug Transport and Resistance Mechanisms (16 papers) and Pharmaceutical studies and practices (10 papers). Robin E. Pearce collaborates with scholars based in United States, Canada and Sweden. Robin E. Pearce's co-authors include J. Steven Leeder, Andrea Gaedigk, Andrew Parkinson, Roger Gaedigk, Gregory L. Kearns, Bhagwat Prasad, Deepak Bhatt, Jorge Goldstein, A. David Rodrigues and A. Parkinson and has published in prestigious journals such as The FASEB Journal, Journal of Pharmacology and Experimental Therapeutics and Journal of Chromatography A.

In The Last Decade

Robin E. Pearce

58 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robin E. Pearce United States	29	1.3k	631	621	467	447	58	2.4k
Su Duan United States	26	1.6k 1.2×	531 0.8×	761 1.2×	534 1.1×	458 1.0×	43	2.9k
A. David Rodrigues United States	31	1.1k 0.9×	647 1.0×	1.3k 2.1×	444 1.0×	404 0.9×	73	2.5k
Miki Katoh Japan	31	1.2k 0.9×	469 0.7×	949 1.5×	827 1.8×	247 0.6×	86	2.5k
George K. Dresser Canada	28	1.4k 1.1×	886 1.4×	1.5k 2.3×	518 1.1×	584 1.3×	59	3.9k
A. David Rodrigues United States	33	1.8k 1.3×	362 0.6×	1.1k 1.8×	619 1.3×	406 0.9×	68	3.0k
Olavi Pelkonen Finland	29	1.3k 1.0×	323 0.5×	560 0.9×	673 1.4×	294 0.7×	68	2.7k
J. Andrew Williams United States	21	1.6k 1.2×	440 0.7×	1.1k 1.8×	679 1.5×	224 0.5×	31	2.6k
Theunis C. Goosen United States	30	1.8k 1.4×	514 0.8×	1.2k 1.9×	756 1.6×	246 0.6×	62	3.0k
Kathleen Knights Australia	27	1.3k 1.0×	256 0.4×	727 1.2×	734 1.6×	388 0.9×	55	2.2k
Ruth Hyland United Kingdom	24	1.5k 1.1×	289 0.5×	734 1.2×	639 1.4×	300 0.7×	31	2.5k

Countries citing papers authored by Robin E. Pearce

Since Specialization

Citations

This map shows the geographic impact of Robin E. Pearce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin E. Pearce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin E. Pearce more than expected).

Fields of papers citing papers by Robin E. Pearce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin E. Pearce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin E. Pearce. The network helps show where Robin E. Pearce may publish in the future.

Co-authorship network of co-authors of Robin E. Pearce

This figure shows the co-authorship network connecting the top 25 collaborators of Robin E. Pearce. A scholar is included among the top collaborators of Robin E. Pearce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin E. Pearce. Robin E. Pearce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gaedigk, Andrea, Susan M. Abdel‐Rahman, Vincent S. Staggs, et al.. (2024). Influence of novel CYP2C‐haplotype on proton pump inhibitor pharmacokinetics in children. Clinical and Translational Science. 17(4). e13782–e13782. 2 indexed citations

Pearce, Robin E., et al.. (2023). Ontogeny of Scaling Factors for Pediatric Physiologically Based Pharmacokinetic Modeling and Simulation: Cytosolic Protein Per Gram of Liver. Drug Metabolism and Disposition. 51(12). 1578–1582. 1 indexed citations

Leeder, J. Steven, Jean Dinh, Andrea Gaedigk, et al.. (2021). Ontogeny of Scaling Factors for Pediatric Physiology-Based Pharmacokinetic Modeling and Simulation: Microsomal Protein Per Gram of Liver. Drug Metabolism and Disposition. 50(1). 24–32. 14 indexed citations

Bhatt, Deepak, Aanchal Mehrotra, Andrea Gaedigk, et al.. (2018). Age‐ and Genotype‐Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate‐Glucuronosyltransferases in Human Liver. Clinical Pharmacology & Therapeutics. 105(1). 131–141. 90 indexed citations

Shakhnovich, Valentina, et al.. (2018). Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity. Pediatric Obesity. 14(1). 17 indexed citations

Haandel, Leon van, et al.. (2018). Development of a UPLC-MS/MS method for quantitation of metronidazole and 2-hydroxy metronidazole in human plasma and its application to a pharmacokinetic study. Journal of Chromatography A. 4 indexed citations

Bhatt, Deepak, Abdul Basit, Andrea Gaedigk, et al.. (2018). Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex. Drug Metabolism and Disposition. 46(6). 888–896. 46 indexed citations

Bhatt, Deepak, Andrea Gaedigk, Robin E. Pearce, J. Steven Leeder, & Bhagwat Prasad. (2017). Age-dependent Protein Abundance of Cytosolic Alcohol and Aldehyde Dehydrogenases in Human Liver. Drug Metabolism and Disposition. 45(9). 1044–1048. 28 indexed citations

Goldman, Jennifer L., J. Steven Leeder, Leon van Haandel, & Robin E. Pearce. (2015). In Vitro Hepatic Oxidative Biotransformation of Trimethoprim. Drug Metabolism and Disposition. 43(9). 1372–1380. 20 indexed citations

10.

Pearce, Robin E., Roger Gaedigk, Greyson P Twist, et al.. (2015). Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation. Drug Metabolism and Disposition. 44(7). 948–958. 37 indexed citations

11.

Gaedigk, Andrea, et al.. (2010). Discovery of the nonfunctional CYP2D6*31 allele in Spanish, Puerto Rican, and US Hispanic populations. European Journal of Clinical Pharmacology. 66(9). 859–864. 25 indexed citations

12.

Leeder, J. Steven, Robin E. Pearce, Andrea Gaedigk, Anil Modak, & David I. Rosen. (2008). Evaluation of a [¹³C]‐Dextromethorphan Breath Test to Assess CYP2D6 Phenotype. The Journal of Clinical Pharmacology. 48(9). 1041–1051. 26 indexed citations

13.

Pearce, Robin E., Wei Lü, Yongqiang Wang, et al.. (2008). Pathways of Carbamazepine Bioactivation in Vitro. III. The Role of Human Cytochrome P450 Enzymes in the Formation of 2,3-Dihydroxycarbamazepine. Drug Metabolism and Disposition. 36(8). 1637–1649. 79 indexed citations

14.

Blake, Michael, Andrea Gaedigk, Robin E. Pearce, et al.. (2007). Ontogeny of Dextromethorphan O- and N-demethylation in the First Year of Life. Clinical Pharmacology & Therapeutics. 81(4). 510–516. 128 indexed citations

15.

Gaedigk, Andrea, Robin E. Pearce, J. Steven Leeder, et al.. (2007). Identification and Characterization of CYP2D6*56B, an Allele Associated with the Poor Metabolizer Phenotype. Clinical Pharmacology & Therapeutics. 81(6). 817–820. 14 indexed citations

16.

Leeder, J. Steven, Roger Gaedigk, Kenda Marcucci, et al.. (2005). Variability of CYP3A7 Expression in Human Fetal Liver. Journal of Pharmacology and Experimental Therapeutics. 314(2). 626–635. 111 indexed citations

17.

Pearce, Robin E., et al.. (2005). PATHWAYS OF CARBAMAZEPINE BIOACTIVATION IN VITRO: II. THE ROLE OF HUMAN CYTOCHROME P450 ENZYMES IN THE FORMATION OF 2-HYDROXYIMINOSTILBENE. Drug Metabolism and Disposition. 33(12). 1819–1826. 59 indexed citations

18.

Marcucci, Kenda, Robin E. Pearce, Charles L. Crespi, et al.. (2002). Characterization of Cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 Activities toward Model CYP2D6 Substrates Dextromethorphan, Bufuralol, and Debrisoquine. Drug Metabolism and Disposition. 30(5). 595–601. 53 indexed citations

19.

Pearce, Robin E., et al.. (2002). Pathways of Carbamazepine Bioactivation in Vitro I. Characterization of Human Cytochromes P450 Responsible for the Formation of 2- and 3-Hydroxylated Metabolites. Drug Metabolism and Disposition. 30(11). 1170–1179. 114 indexed citations

20.

Lehman‐McKeeman, Lois D., Douglas Caudill, Jeffrey D. Vassallo, et al.. (1999). Effects of musk xylene and musk ketone on rat hepatic cytochrome P450 enzymes. Toxicology Letters. 111(1-2). 105–115. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact